Trials / Withdrawn
WithdrawnNCT04808934
NOAC Portuguese Real World Study
Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Adults receiving apixaban |
| DRUG | dabigatran | Adults receiving dabigatran |
| DRUG | rivaroxaban | Adults receiving rivaroxaban |
| DRUG | VKAs | Adults receiving VKA |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2021-03-22
- Last updated
- 2023-04-05
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04808934. Inclusion in this directory is not an endorsement.